INCY

Incyte Corp
D

INCY

68.470
USD
0.30
(0.44%)
مغلق
حجم التداول
36,676
الربح لكل سهم
6
العائد الربحي
-
P/E
342
حجم السوق
13,253,733,381
أصول ذات صلة
ABBV
ABBV
-1.530
(-0.80%)
189.200 USD
A
AGIO
0.645
(1.82%)
36.020 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
المزيد
الأخبار المقالات

العنوان: Incyte Corp

القطاع: Healthcare
الصناعة: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.